CA2513731A1 - Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases - Google Patents

Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases Download PDF

Info

Publication number
CA2513731A1
CA2513731A1 CA002513731A CA2513731A CA2513731A1 CA 2513731 A1 CA2513731 A1 CA 2513731A1 CA 002513731 A CA002513731 A CA 002513731A CA 2513731 A CA2513731 A CA 2513731A CA 2513731 A1 CA2513731 A1 CA 2513731A1
Authority
CA
Canada
Prior art keywords
compound
formula
beta
combination
corticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513731A
Other languages
English (en)
French (fr)
Inventor
Anthony Winiski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302991A external-priority patent/GB0302991D0/en
Priority claimed from GB0316436A external-priority patent/GB0316436D0/en
Application filed by Individual filed Critical Individual
Publication of CA2513731A1 publication Critical patent/CA2513731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CA002513731A 2003-02-10 2004-02-09 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases Abandoned CA2513731A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0302991A GB0302991D0 (en) 2003-02-10 2003-02-10 Organic compounds
GB0302991.5 2003-02-10
GB0316436A GB0316436D0 (en) 2003-07-14 2003-07-14 Organic compounds
GB0316436.5 2003-07-14
PCT/EP2004/001179 WO2004069267A1 (en) 2003-02-10 2004-02-09 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases

Publications (1)

Publication Number Publication Date
CA2513731A1 true CA2513731A1 (en) 2004-08-19

Family

ID=32852416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002513731A Abandoned CA2513731A1 (en) 2003-02-10 2004-02-09 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases

Country Status (6)

Country Link
US (1) US20060083754A1 (https=)
EP (1) EP1594522A1 (https=)
JP (1) JP2006517217A (https=)
BR (1) BRPI0407350A (https=)
CA (1) CA2513731A1 (https=)
WO (1) WO2004069267A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1941911A4 (en) * 2005-10-28 2011-01-12 Kowa Co METHOD FOR THE PREVENTION AND / OR TREATMENT OF RHEUMATOID ARTHRITIS
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
WO2011054399A1 (en) * 2009-11-06 2011-05-12 Avail Gmbh Improvement of the glucocorticoid receptor function in asthma
WO2022242741A1 (en) * 2021-05-20 2022-11-24 Chengdu Anticancer Bioscience, Ltd. Methods comprising administration of a glucocorticoid receptor agonist and an inhibitor of calcineurin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
US5215965A (en) * 1990-10-02 1993-06-01 John Lezdey Treatment of inflammation
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
JP2001510485A (ja) * 1999-03-01 2001-07-31 シェーリング コーポレイション アトピー性皮膚炎、血管性浮腫および他の障害を抗ヒスタミン薬およびグルココルチコイドを用いて処置するための組成物および方法

Also Published As

Publication number Publication date
JP2006517217A (ja) 2006-07-20
WO2004069267A1 (en) 2004-08-19
EP1594522A1 (en) 2005-11-16
BRPI0407350A (pt) 2006-01-10
US20060083754A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
Meneghini et al. Immunosuppressive drugs modes of action
TWI760331B (zh) 可溶性C5aR拮抗劑
US10406148B2 (en) Methods of treatment using a JAK inhibitor compound
EP3958969B1 (en) Ester and carbonate pyrimidine compounds as jak kinase inhibitors
ES2225919T3 (es) Derivados de rapamicina y su uso, en particular como inmunosupresores.
CN108601790B (zh) C3肾小球病的治疗方法
JP2581359B2 (ja) 懸濁性組成物
SK122199A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
RU2130460C1 (ru) Производные тетрагидропирана и фармацевтическая композиция на их основе
JP2007254483A (ja) マクロライド類
KR20150128856A (ko) 스테로이드 약물과 결합된 항생제 컨쥬게이트
US20220306626A1 (en) Crystalline form of a dihydrochloride salt of a jak inhibitor compound
CA2513731A1 (en) Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases
CA2442969A1 (en) Methods for selective immunomodulation using pimecrolimus
Tönshoff et al. Immunosuppression in pediatric kidney transplantation
JP2007506681A (ja) 抗ｉｌ−２受容体抗体による呼吸器疾患の治療
CN105073140A (zh) 与类固醇药物直接键联的抗生素缀合物
Brynskov Cyclosporin for inflammatory bowel disease: mechanisms and possible actions
Fukudo et al. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection
Schuurman C12 Immunosuppressives in transplant rejection
Levy et al. Modern Immunosuppressives 11 ed. by H.-J Schuurman, G. Feutren and J.-F. Bach© 2001 Birkhäuser Verlag/Switzerland
EP1649856A2 (en) Use of pimecrolimus for selective immunomodulation
PLUMMERIDGE et al. 22 Immunomodulators in the Treatment of Asthma
Hong et al. The potential role of immunosuppressive macrocyclic lactones
Durrani et al. MAJOR REVIEW

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued